tradingkey.logo

Kyverna Therapeutics falls on $100 mln stock sale plans

ReutersDec 15, 2025 9:38 PM

Kyverna Therapeutics' KYTX.O shares down 6.9% in extended trading to $10.08 following planned equity raise news

Emeryville, California-based KYTX announces proposed $100 mln stock offering

KYTX stock surged 23.2% to close at $10.82 on Mon after co said its experimental cell therapy, miv-cel, for treatment of a rare movement disorder met the main goal in a mid-stage study

Co has ~43.8 mln shares outstanding for roughly $475 mln market cap

J.P. Morgan, Leerink, Morgan Stanley and Wells Fargo are joint book-running managers for the offering

Through Mon, shares have nearly tripled YTD

All 6 analysts are bullish including 2 "strong buy" ratings; median PT of $29 up from $22.50 on Nov 15, per LSEG data

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI